Adcendo

Welcome to Adcendo, Malene!   As our team continues to grow, we are excited to welcome our new team member, Malene Pedersen, who has joined us as Technician. We look forward to the exciting journey ahead as we make strides towards better treatment of cancer. 🚀🔬 Follow our Company LinkedIn page for news and information about upcoming open positions.   #Adcendo #Welcome #TeamGrowth #NewBeginnings

📣 PRESS RELEASE📣 This morning we are sharing some very exciting news from Adcendo!   Today, we announce a licensing agreement with Multitude Therapeutics for the development of a novel, highly differentiated antibody-drug conjugate (#ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.   TF is a clinically validated ADC target that is highly expressed in indications such as non-small cell lung cancer, colorectal cancer, cervical cancer, oesophageal cancer, head and neck cancer, bladder cancer and certain gastrointestinal cancers, but its expression is limited in normal tissues.   ADCE-T02 is a highly differentiated anti-TF ADC, and the first ADC with a Topoisomerase I inhibitor-based linker/payload, to enter into clinical development in Australia, US and Europe. The start of the Phase I study in Australia is expected in Q4 2024, thereby transitioning Adcendo into a clinical stage biotech company.   Read the full press release to discover how the licensing agreement perfectly complements Adcendo's existing unique first-in-class ADC pipeline via the link below! https://lnkd.in/d2uTpb6j   #biotech #cancer #oncology #lifesciences

🎺 Job Opening 🎺 We are recruiting a Scientist to help us characterize expression levels of target proteins of interest, contributing to our growing pipeline of novel drugs of the ADC (antibody-drug conjugate) type. The ideal candidate has 2-5 years of relevant and dedicated hands-on experience with associated core techniques such as IHC and ISH, preferably from a biotech/pharma/CRO environment, including analysis and evaluation of the resulting data. 👩🔬 See the job ad via this link, and apply via e-mail. 👨🔬 https://lnkd.in/dSVZJaEn #Adcendo #ADCs #cancer #careeropportunity #jobopening #scientist #copenhagen

Are you ready to lead the charge in groundbreaking cancer research and drug development? Adcendo is on the hunt for a dynamic Project Manager/Lead (Director) to spearhead a full R&D project team for a development project in clinical phase 1 stage. As the driving force behind a cutting-edge project, you'll play a pivotal role in helping shape the future of cancer treatment. At Adcendo, we are dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers. We pride ourselves on being at the forefront of cutting-edge technologies and solutions, and our commitment to excellence sets us apart. We offer an international work environment that fosters innovation and rewards excellence. This is a fantastic opportunity to contribute to the future of cancer treatment as part of a forward-thinking company! Find more details about the job and how to apply: https://lnkd.in/dJ8E9UNd #ClinicalDevelopment #ProjectLead #Adcendo #Cancer #ADC #CareerOpportunity #JobOpening

We are seeking a toxicologist to join our team as Associate Director/Director of Toxicology. At Adcendo, we are dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers. We pride ourselves on being at the forefront of cutting-edge technologies and solutions, and our commitment to excellence sets us apart. As Associate Director/Director of Toxicology you will be responsible for all Toxicology & Safety aspects of selected Adcendo ADC programs. You will work closely with our pre-clinical & clinical departments to support the progression of product candidates all the way from late-stage research through to pivotal human clinical trials. We offer an international work environment that fosters innovation and rewards excellence. This is a fantastic opportunity to contribute to the future of cancer treatment as part of a forward-thinking company! Find more details about the job and how to apply: https://lnkd.in/dwH2k4Hu #Toxicology #Adcendo #Cancer #ADC #CareerOpportunity #JobOpening

Please do not miss this open opportunity for joining Adcendo as a #toxicologist. Do not hesitate to us apply via LinkedIn or e-mail, as we aim to kick off interviews after the holiday weeks.

Adcendo Stands with the Sarcoma Community: Advancing Innovation for a Brighter Future This July, as we observe Sarcoma Awareness Month, Adcendo reaffirms our commitment to the global fight against sarcoma. Sarcoma Awareness Month is a powerful reminder of the strength and resilience of those affected by this rare group of cancers, and it is a call to action for all to raise awareness and drive innovation. At Adcendo, we are pioneering the development of Antibody-Drug Conjugates (ADCs) specifically designed to target rare cancers such as sarcomas. Our mission is to transform the treatment landscape for sarcoma patients by harnessing the power of ADC technology to deliver targeted, effective therapies. Our lead program focuses on uPARAP (urokinase plasminogen activator receptor-associated protein), a novel and promising target for cancer treatment, underscoring our dedication to addressing the unmet needs in sarcoma care. We believe that through cutting-edge research and collaboration, we can make a significant impact. This Sarcoma Awareness Month, we invite patients, families, caregivers, healthcare professionals, researchers, policymakers, and the broader community to join us in our mission. Together, we can honour those who have battled sarcoma, support those currently fighting, and work towards a future where early detection, effective treatment, and ultimately, a cure for sarcoma, are within reach. Join Adcendo in standing with the sarcoma community and reinforcing our collective commitment to innovative cancer treatment solutions. #SarcomaAwarenessMonth #Adcendo #InnovationInAction #CancerResearch #ADCTechnology #HopeForACure

Please join us in welcoming our newest team member, Sandra Thomas Frederiksen, who has joined us as Executive Assistant. Her extensive experience supporting leaders in the Biotech industry will undoubtedly contribute to our success! Welcome to Adcendo, Sandra! We look forward to the exciting journey ahead as we make strides towards better treatment of cancer. 🚀 Follow our Company LinkedIn page for news and information about upcoming open positions. #Adcendo #NewHire #CancerResearch #ADCs #ExecutiveAssistant #WeAreGrowing

Great to see our CEO, Michael Pehl, highlighted by Clarivate following the publication of its 'Companies to Watch: Antibody Drug Conjugates' report! https://lnkd.in/dbTeNsct Learn more about Adcendo and our development of first-in-class #ADCs for the treatment of #cancer with a high unmet medical need in the report here: https://lnkd.in/eWhSzAWz #biotech #oncology #lifesciences

📣 Adcendo has been featured in Clarivate for Life Sciences & Healthcare's "Companies to Watch: Antibody Drug Conjugates" report! 📰 The report highlights this exciting field of therapeutics and shines a spotlight on companies making an impact in the #lifesciences and #healthcare space. Adcendo is highlighted as one of seven companies that are advancing antibody-drug conjugates (#ADCs) to deliver highly targeted cancer treatments with an improved therapeutic window. Find out more about what makes us stand out, our R&D activities to date, and much more in the report here: https://lnkd.in/eWhSzAWz #biotech #oncology #lifesciences